The European Medicines Agency's controversial procedure on checking partial compliance of pediatric investigation plans prepared by drug companies under the EU Paediatric Regulation has been formally endorsed by the European Commission1. Whether the companies like it or not, the procedure is here to stay.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?